[1. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149-1158.10.1002/cncr.27834]Search in Google Scholar
[2. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23:3155-3162.10.1093/annonc/mds181]Open DOISearch in Google Scholar
[3. Clemons NJ, Phillips WA, Lord RV. Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther. 2013;14:782-795.10.4161/cbt.25362]Open DOISearch in Google Scholar
[4. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.10.1038/366704a0]Search in Google Scholar
[5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.10.1016/S0092-8674(00)81683-9]Open DOISearch in Google Scholar
[6. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.10.1126/science.8153634]Search in Google Scholar
[7. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, De-Pinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85:27-37.10.1016/S0092-8674(00)81079-X]Search in Google Scholar
[8. Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16:1197-1206.10.1200/JCO.1998.16.3.11979508208]Search in Google Scholar
[9. Romagosa C, Simonetti S, López-Vicente L, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011;30:2087-2097.10.1038/onc.2010.61421297668]Open DOISearch in Google Scholar
[10. Nobori T, Miura K, Wu D, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753-756.10.1038/368753a08152487]Search in Google Scholar
[11. Liu Q, Yan YX, McClure M, Nakagawa H, Fujimura F, Rustgi AK. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene. 1995;10:619-622.]Search in Google Scholar
[12. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.10.1126/science.8153634]Search in Google Scholar
[13. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995;11:210-212.10.1038/ng1095-210]Open DOISearch in Google Scholar
[14. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett’s esophagus. Oncogene. 1996;13:1867-1873.]Search in Google Scholar
[15. González MV, Artímez ML, Rodrigo L, et al. Mutation analysis of the p53, APC, and p16 genes in the Barrett’s oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol. 1997;50:212-217.10.1136/jcp.50.3.212]Search in Google Scholar
[16. Lu Y, Zhang X, Zhang J. Inhibition of breast tumor cell growth by ectopic expression of p16/INK4A via combined effects of cell cycle arrest, senescence and apoptotic induction, and angiogenesis inhibition. J Cancer. 2012;3:333-344.10.7150/jca.4046]Open DOISearch in Google Scholar
[17. Hu H, Li Z, Chen J, et al. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating Akt/survivin signalling in hepatocellular carcinoma cells. Gut. 2011;60:710-721.10.1136/gut.2010.220020]Open DOISearch in Google Scholar
[18. Allay JA, Steiner MS, Zhang Y, Reed CP, Cockroft J, Lu Y. Adenovirus p16 gene therapy for prostate cancer. World J Urol. 2000;18:111-120.10.1007/s003450050182]Open DOISearch in Google Scholar
[19. Schrump DS, Chen GA, Consuli U, Jin X, Roth JA. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Cancer Gene Ther. 1996;3:357-364.]Search in Google Scholar
[20. Xie SH, Lagergren J. A global assessment of the male predominance in esophageal adenocarcinoma. Oncotarget. 2016;7:38876-38883.10.18632/oncotarget.9113]Search in Google Scholar
[21. Bollschweiler E, Wolfgarten E, Gutschow C, Hölscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92:549-555.10.1002/1097-0142(20010801)92:3<549::AID-CNCR1354>3.0.CO;2-L]Open DOISearch in Google Scholar
[22. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232-248.10.3322/caac.21185]Open DOISearch in Google Scholar
[23. Duraiyan J, Govindarajan R, Kaliyappan K, Palanisamy M. Applications of immunohistochemistry. J Pharm Bioallied Sci. 2012;4(Suppl 2):S307-9.10.4103/0975-7406.100281]Search in Google Scholar
[24. Le Beau MM. Fluorescence in situ hybridization in cancer diagnosis. Important Adv Oncol. 1993;29-45.]Search in Google Scholar
[25. Hu L, Ru K, Zhang L, et al. Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. Biomark Res. 2014;2:3.10.1186/2050-7771-2-3]Search in Google Scholar
[26. Trask BJ. Fluorescence in situ hybridization: applications in cytogenetics and gene mapping. Trends Genet. 1991;7:149-154.10.1016/0168-9525(91)90378-4]Open DOISearch in Google Scholar
[27. Waters JJ, Barlow AL, Gould CP. Demystified ... FISH. Mol Pathol. 1998;51:62-70.10.1136/mp.51.2.623956129713588]Search in Google Scholar
[28. Langer R, Von Rahden BH, Nahrig J, et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol. 2006;59:631-634.10.1136/jcp.2005.034298186040116731604]Search in Google Scholar
[29. Hardie LJ, Darnton SJ, Wallis YL, et al. p16 expression in Barrett’s esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett. 2005;217:221-230.10.1016/j.canlet.2004.06.02515617840]Search in Google Scholar
[30. Doak SH, Jenkins GJS, Parry EM, et al. Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. Br J Cancer. 2003;89:1729-1735.10.1038/sj.bjc.6601323239441414583777]Search in Google Scholar
[31. Zordan A. Fluorescence in situ hybridization on formalin-fixed, paraffin-embedded tissue sections. Methods Mol Biol. 2011;730:189-202.10.1007/978-1-61779-074-4_1421431643]Search in Google Scholar
[32. Brankley SM, Wang KK, Harwood AR, et al. The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett’s esophagus. J Mol Diagn. 2006;8:260-267.10.2353/jmoldx.2006.050118186758216645214]Search in Google Scholar
[33. Fahmy M, Skacel M, Gramlich TL, et al. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett’s esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol. 2004;17:588-596.10.1038/modpathol.380008815017433]Search in Google Scholar
[34. Doak SH, Jenkins GJ, Parry EM, et al. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett’s oesophagus. Gut. 2003;52:623-628.10.1136/gut.52.5.623177363712692043]Search in Google Scholar
[35. Brankley SM, Fritcher EG, Smyrk TC, et al. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett’s esophagus with high-grade dysplasia or adenocarcinoma. Hum Pathol. 2012;43:172-179.10.1016/j.humpath.2011.04.018]Open DOISearch in Google Scholar
[36. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett’s esophagus. Cancer Res. 2004;64:3414-3127.10.1158/0008-5472.CAN-03-3249]Open DOISearch in Google Scholar
[37. Wang JS, Guo M, Montgomery E, et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett’s esophagus. Am J Gastroenterol. 2009;104:2153-2160.10.1038/ajg.2009.300]Search in Google Scholar
[38. Klump B, Hsieh CJ, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett’s esophagus. Gastroenterology. 1998;115:1381-1386.10.1016/S0016-5085(98)70016-2]Search in Google Scholar
[39. Wong DJ, Barrett MT, Stöger R, Emond MJ, Reid BJ. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res. 1997;57:2619-2622.]Search in Google Scholar